Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | casein kinase II, putative | 0.1033 | 1 | 0.5 |
Loa Loa (eye worm) | CMGC/CK2 protein kinase | 0.1033 | 1 | 1 |
Trypanosoma brucei | Casein kinase II | 0.1033 | 1 | 1 |
Echinococcus multilocularis | casein kinase ii subunit alpha | 0.1033 | 1 | 0.5 |
Schistosoma mansoni | protein kinase | 0.1033 | 1 | 0.5 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.1033 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1033 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1033 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1033 | 1 | 0.5 |
Echinococcus granulosus | casein kinase ii subunit alpha | 0.1033 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1033 | 1 | 0.5 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.1033 | 1 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.1033 | 1 | 0.5 |
Onchocerca volvulus | 0.0295 | 0.2582 | 0.5 | |
Entamoeba histolytica | casein kinase, putative | 0.1033 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1033 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1033 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.1033 | 1 | 0.5 |
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.1033 | 1 | 0.5 |
Plasmodium vivax | unspecified product | 0.1033 | 1 | 0.5 |
Giardia lamblia | Kinase, CMGC CK2 | 0.1033 | 1 | 0.5 |
Leishmania major | casein kinase II, putative | 0.1033 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 0 % | Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures at 100 mg/kg, ip administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to control | ChEMBL. | No reference |
Activity (functional) | = 20 % | Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures at 75 mg/kg, ip administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to control | ChEMBL. | No reference |
Activity (functional) | = 34.2 % | Anticonvulsant activity in ip dosed Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to phenobarbital | ChEMBL. | No reference |
Activity (functional) | = 60 % | Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures at 50 mg/kg, ip administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to control | ChEMBL. | No reference |
PD50 (functional) | = 55.56 mg kg-1 | Anticonvulsant activity in ip dosed Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.